RE:RE:RE:RE:RE:Does CG0070 have better efficacy than Ruvidar PDT?Well I contextualize this thought process based on where is the successful funding and VC backing; which trials have a plethora of CSS's and rapid enrollment rates? Which companies are generating the industry "buzz", garnering attention and achieving valuations we can only dream on? I think Theralase is viewed as a Mickey Mouse operation and I don't know what alters that perception near term. CR rates head and shoulders above the competition will go a long way toward changing minds and BTD approval could be what finally prompts a BP to begin kicking the tires. Meanwhile patience is expensive, to the tune of $1M+ per quarter. Hopefully they get this pre-BTD locked in near term